STOCK TITAN
  1. Home
  2. News
  3. AURA

Aura Biosciences Inc - AURA STOCK NEWS

Welcome to our dedicated news page for Aura Biosciences (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aura Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aura Biosciences's position in the market.

News
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Rhea-AI Summary
Aura Biosciences, Inc. (NASDAQ: AURA) is enrolling patients in a global Phase 3 CoMpass trial for small choroidal melanoma and indeterminate lesions, with data expected in mid-2024. The company has a strong cash position until the second half of 2026. Bel-sar, a potential vision-and-organ sparing therapy, is being expanded into bladder cancer, addressing major unmet medical needs in ocular oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
earnings
-
News
Aura Biosciences to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Aura Biosciences Inc. (NASDAQ: AURA) announced CEO Elisabet de los Pinos will participate in investor conferences. The company develops virus-like drug conjugate therapies for oncology. Webcasts of the conferences will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
conferences
-
News
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
Rhea-AI Summary
Aura Biosciences Inc. (NASDAQ: AURA) has announced the dosing of the first patient in the global Phase 3 CoMpass trial for bel-sar, a novel VDC therapy for early-stage choroidal melanoma. The trial, with an FDA SPA agreement, aims to evaluate the safety and efficacy of bel-sar as a first-line treatment for this rare disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
clinical trial
News
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
Rhea-AI Summary
Aura Biosciences, Inc. (NASDAQ: AURA) received FDA agreement under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical Trial, presenting positive clinical efficacy updates of Bel-sar for early-stage choroidal melanoma. The company also raised gross proceeds of $99.0 million in an underwritten public offering. Positive clinical efficacy updates and financial results for the third quarter were highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.54%
Tags
earnings clinical trial
-
News
Aura Biosciences to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Aura Biosciences Inc. (NASDAQ: AURA) CEO to participate in investor conferences, including Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference. Live webcasts and replays available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
conferences
-
News
Aura Biosciences Announces Pricing of Public Offering of Common Stock
Rhea-AI Summary
Aura Biosciences, Inc. (Nasdaq: AURA) has announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at $9.00 per share. The gross proceeds from the offering are expected to be $99.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.55%
Tags
offering
News
Aura Biosciences Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Aura Biosciences, Inc. has announced the launch of an underwritten public offering of its common stock. The offering is subject to market conditions and will be made by means of a written prospectus and prospectus supplement. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares. Leerink Partners, TD Cowen, and Evercore ISI are acting as joint bookrunning managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.55%
Tags
offering
-
News
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
Rhea-AI Summary
Aura Biosciences announces positive Phase 2 data and FDA agreement for bel-sar in the treatment of early-stage choroidal melanoma. The Phase 2 trial shows 80% tumor control and 90% visual acuity preservation. The FDA has agreed to the design and analysis of the Phase 3 trial. Preliminary data from a Phase 1 trial in bladder cancer shows a clinical complete response with bel-sar.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.18%
Tags
clinical trial
-
News
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
Rhea-AI Summary
Aura Biosciences Inc. (NASDAQ: AURA) will present updated data from the Phase 2 trial of its first VDC product candidate, bel-sar, for the treatment of early-stage choroidal melanoma at the AAO 2023 Annual Meeting. The presentation will be given by Dr. Carol L. Shields from Wills Eye Hospital on November 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.93%
Tags
conferences clinical trial
News
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
Rhea-AI Summary
Aura Biosciences announces the appointment of Jill Hopkins, M.D., as Chief Medical Officer and President of Research & Development, and Mark Plavsic, Ph.D., as Chief Technology Officer. Cadmus Rich, M.D., will step down as Chief Medical Officer and assume a new role as Senior Clinical Advisor. Aura's goal is to bring the first vision-preserving targeted therapy for patients with early-stage choroidal melanoma to market. Hopkins brings over 30 years of experience in ophthalmology, while Plavsic has 30 years of global biopharmaceutical experience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
management
Stock AURA logo
Aura Biosciences Inc

Nasdaq:AURA

AURA Rankings

#3247 Ranked by Market Cap
#4398 Ranked by Stock Gains
N/A Ranked by Dividends

AURA Stock Data

359.40M
30.96M
7.69%
83.26%
4.94%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Boston

About AURA

at aura biosciences, we are developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed – an approach we call molecular surgery. by safely eliminating cancer locally, we can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. our lead program in ocular melanoma (om), also known as choroidal or uveal melanoma, is designed to remove cancer cells in the back of the eye as a first-line therapy, while allowing for the potential of preserving patients’ vision. the goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. development of a first-in-class, non-radioactive treatment option to selectively destroy cancer cells would create the possibility to transform the treatment of this and other cancers where the disease can be detected early. by enabling physicians to treat cancer mo